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Abstract: Headaches in children and adolescents are still under-diagnosed. 75% of children are 
affected by primary headache by the age of 15 with 28% ﬁ  tting the ICHD2 criteria of migraine. 
Migraine is considered a chronic disorder that can severely impact a child’s daily activities, 
including schooling and socializing. Early recognition and aggressive therapy, with acute and 
prophylactic treatments, as well as intensive biobehavioral interventions, are essential to control 
the migraine attacks and reverse the progression into intractable disabling headache.
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Introduction
Primary headache, especially migraine, has been under-diagnosed in children and ado-
lescents. Migraine is not a rare disease in this age group: 10% of children are affected 
by migraine headaches, and up to 75% of children by the time they are 15 years old 
report having a signiﬁ  cant headache (Bille 1962), which is described as intolerable 
pain that prevents them from any activity, including going to school or to social events. 
28% of these children appear to have migraine (Split and Neuman 1999). This very 
common disorder has a signiﬁ  cant impact on a child’s life and school performance, 
as well their relationship with their family and peers. The impact of this disease can 
result in school absenteeism and lack of involvement in peer activities, and can have 
long term socioeconomic and possibly biological consequences. Early recognition 
and intervention with appropriate treatment is essential to minimize this impact on a 
child’s quality of life, and may be important in preventing long term disability.
Epidemiology
Headaches are very common in childhood. Based on the study of 8993 children between 
1957–1961, Bille (1962) found that 40% of children had a signiﬁ  cant headache before 
the age of 7, while 75% had a signiﬁ  cant headache before the age of 15. Approximately 
4% of these patients between the ages of 7 and 15 were believed to have migraines. In 
a meta-analysis of childhood headaches examining over 27,000 children, 37%–51% of 
children by the age of 7 reported a signiﬁ  cant headache, while 57%–82% of children 
reported a signiﬁ  cant headache by the age of 15 (Lewis et al 2002a).
Abu-Arafeh and Russell (1994) reported that 10.6% of children had signiﬁ  cant 
headaches consistent with migraine between the ages of 5–15, with an increasing one 
year prevalence between the ages of 10 and 19. In the meta-analysis of pediatric head-
ache, between 1.2% and 3.2% of children between the ages of 3 and 7 had migraines 
with a slight male predominance (Lewis et al 2002a). Between the ages of 7 and 11, 
this increased to between 4 and 11%, with an equal male and female predominance; and 
between 11 and 15 this increased to 18%–23%, with a female predominance developing. 
In the 15–19 year old age range, Split and Newman (1999) looked at 2353 children in 
Lodz, Poland, using the ICHD-I criteria. This study found that 28% of these adolescents 
had migraines with a female predominance. Of the adolescents with migraine, 19% had 
migraine without aura and 9% had migraine with aura. Mixed headaches were seen Neuropsychiatric Disease and Treatment 2008:4(3) 536
Kabbouche and Gilman
in 6.3% had with some tension-type headaches in addition 
to migraines. There was a strong family history with 81% 
of the adolescents with migraine with nearly a quarter of 
the females in this group having a menstrual relationship 
with their headaches. In addition, status migrainosus was 
noted in 14.8% of the girls, and 4.7% of the boys (Split and 
Neuman 1999).
Pathophysiology
The pathophysiology of migraine headache remains undeﬁ  ned. 
Several theories as to the underlying pathophysiology are being 
developed. One aspect of migraine that is clear is its genetic 
nature (Montagna 2004). Twin studies and family studies have 
demonstrated a high degree of inheritance, reporting a history of 
migraine as high as 90% in ﬁ  rst or second degree relatives. For 
familial hemiplegic migraine, three genes have been identiﬁ  ed 
as contributing to the disorder in several kindreds: P/Q Calcium 
channel (CACNA1A), ATPase (ATP1A2), and sodium chan-
nel (SCN1A) (Dichgans et al 2005). There has been suggested 
linkage with some of these genes in familial migraine with 
aura, yet a consistent gene defect in migraine without aura or 
migraine with aura has not yet been identiﬁ  ed.
The trigeminal neurovascular system’s involvement with 
migraine has been proposed as a unifying theory of migraine. 
This model has been supported by several imaging studies 
that have demonstrated involvement of the brainstem near 
the trigeminal nuclease and the peri-aquaductal gray (Welch 
et al 1998).
The pathophysiology of tension type headaches (TTH) in 
children should be similar to that seen in adults. Two theories 
exist relating migraines and TTH. The continuum model 
suggests that migraine and TTH are one pathophysiological 
disorder ranging from mild headaches that appear to be TTH, to 
the most severe headaches that represent migraines associated 
with aura (Cady et al 2002). This is contrast to the Spectrum 
model, which suggests that these are two separate entities, with 
the migraine patients experiencing a full spectrum of headaches, 
while TTH patients have headaches limited to the aforemen-
tioned mild to moderate pain disorder (Lipton et al 2000a).
With TTH, there may be a secondary muscle contraction 
component, and some suggestion has been provided that this 
could enhance a feedback loop, building the TTH (Langemark 
and Olesen 2000). Recently,the role of central sensitization and 
other alternative theories have been reviewed (Jensen 1999).
Diagnosis
In order standardize the diagnosis, criteria were developed 
and were revised at the International Headache Society in 
Italy, 2003, to better ﬁ  t the diagnosis of headache in children 
and adolescents. Previous criteria were lacking sensitivity 
and speciﬁ  city in diagnosing childhood headache (ICHD-1) 
(IHS 1988). The suggestions adopted in the second edition 
of the ICHD criteria (ICHD-II) (IHS 2004) to make the 
criteria more sensitive to childhood headache included a 
shorter duration, lack of some associated symptoms due to 
the description of difﬁ  culties faced by children, as well as the 
bilateral location of the headache as opposed to the unilateral 
location in adults. The validity of the ICHD-II has yet to be 
fully assessed for children. It does appear to be an improve-
ment, although indications are that it remains incomplete in 
diagnosing primary headache disorders in children (Hershey 
et al 2005). However, given these limitations, the ICHD-II is 
the current foundation for the diagnosis and scientiﬁ  c study 
of headache and migraine. Headaches are divided through 
the ICHD-1 criteria as primary and secondary.
Primary headaches
Migraine headache
The ICHD-II criteria subdivide migraine into migraine 
without aura and migraine. In addition, migraine includes 
migraine variants, such as the periodic syndromes of child-
hood, and probable migraine, when not all of the features of 
migraine are met. The ICHD-II also added the category of 
chronic migraine, deﬁ  ned as frequent headaches – at least 
15 times per month for the previous three months – with 
migraine features that could not be attributed to a second-
ary cause.
Tension-type headache
Tension-type headaches are generally considered mild, 
recurrent headaches, and many features are the opposite of 
migraine. In the past, they have been called muscle contrac-
tion headache, idiopathic headache, tension headaches and 
“stress headache”. They can be subdivided into infrequent, 
frequent, and chronic based on the frequency of the head-
aches. The headaches themselves are usually described as 
mild and moderate in severity, diffuse in location, and have a 
pressing quality. No associated symptoms and no secondary 
causes are identiﬁ  ed.
Impact of migraine
Primary headaches and migraines can have a signiﬁ  cant 
impact on a child’s life. The impact of a migraine can be 
measured by both the loss of ability to participate in activities, 
as well as the effect on quality of life. In the 1989 National 
Health Interview Survey, it was found that for adults, there Neuropsychiatric Disease and Treatment 2008:4(3) 537
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are three million bedridden days per month in the United 
States, with 56% of these adults missing at least two days of 
work per month due to their migraines (Stang and Osterhaus 
1993). This same survey evaluated the impact of childhood 
headaches and found that within a two-week period, 975,000 
children had a migraine, resulting in 164,454 missed school 
days within this two-week period.
Headache can affect all aspects of a child’s functioning, 
leading to negative affective states (eg, anxiety, depression, 
anger) and increased psychosocial problems (eg, school 
absences, problematic social interactions). Although the 
vast majority of children who experience headaches, includ-
ing those who report recurrent headaches, do not display a 
diagnosable psychiatric condition, a few of these patients, 
upon presentation for treatment of headache, are exhibit-
ing symptoms that indicate the presence of a comorbid 
psychological/psychiatric condition such as an anxiety 
disorder or depression.
For children who experience frequent headache problems, 
the relationship between headache and psychiatric symptoms 
has not been well deﬁ  ned. Although global conclusions 
about psychopathology in children with headaches have been 
advanced, the mechanisms underlying these associations 
remain poorly understood. Speciﬁ  cally, whether psychiatric 
disorders are a causal factor in the development of headache, 
whether headache is a causal factor in the development of 
psychiatric disorders (eg, frequent and severe pain leads to 
anticipatory anxiety, perceived loss of control, frustration, or 
other risk factors for psychopathology), or whether a common 
shared etiological factor may explain both without a causal 
association between them (eg, biological or neurotransmitter) 
are unresolved hypotheses. Evolving research is beginning 
to examine longitudinally the relation between headache 
and psychopathology in youth, but conclusions pertinent to 
practice are premature at this time.
Several tools have been developed to evaluate the disabil-
ity of migraine. In adults this can be addressed with MIDAS 
(MIgraine Disability ASsessment) (Stewart et al 1999, 2000, 
2001; Lipton et al 2001). This tool measures headache-related 
disability using three domains – work, household work and 
nonwork or social activities – over a 3-month recall period. 
MIDAS has been found to be quite useful in assessing dis-
ability in adults and has been used in long term studies to 
demonstrate any change in disability or treatment, as well 
as the development of new treatment strategies, including 
the Stratiﬁ  ed Care Model (Lipton et al 2000b; Lipton and 
Silberstein 2001). A simpliﬁ  ed scoring system for MIDAS 
has been developed, with four levels of disability.
For children, however, MIDAS was inadequate, due to the 
differences in lifestyles of children. Consequently, PedMI-
DAS was developed (Hershey et al 2001). The PedMIDAS 
evaluates three similar domains to the adult scale (ie, 
MIDAS), but the measure was adapted to correspond more 
with pediatric populations. For instance, on the PedMIDAS 
the school affect domain was augmented to include three 
questions assessing days that were fully missed, days that 
were partially missed, and days where the child remained in 
school but had diminished functioning due to the migraine. 
In the home effects domain, only one question was retained 
from the MIDAS: those days where the child is unable to 
perform home activities such as chores in the household and 
homework. Finally, the social effect domain was increased to 
two questions, with one assessing days where the child was 
unable to participate in social activities such as interacting 
with friends and sporting activities, and the other assessing 
days where the child was only able to participate at 50% 
of their abilities. The scoring system was based on patient-
based disability and had a greater score range than MIDAS 
due to the child’s increased ability to miss out on activities 
(Hershey et al 2004).
The use of MIDAS for adults and PedMIDAS for children 
can be highly effective in assessing the disability of migraine 
and subsequent treatment and outcomes. One recent study 
found that PedMIDAS was a useful tool in assessing treat-
ment strategies, with an improvement in PedMIDAS scores 
demonstrated with use of prophylactic medication (Hershey 
et al 2002).
Quality of life
Assessing health-related quality of life (QoL) is another way 
to evaluate the impact of a disease. QoL is a multidimensional 
construct that reﬂ  ects the impact of disease and treatment on 
a patient’s subjective evaluation of his or her functioning and 
emotional well-being (Bandell-Hoekstra et al 2000). Initial 
studies with adults found that headache sufferers evidence 
reduced mental health functioning, as well as poor physical, 
social, and role functioning. In one such study assessing QoL 
in adult patients with migraine headaches in comparison to 
other chronic diseases, such as hypertension, diabetes, angina 
and myocardial infarction, it was found that patients with 
migraines reported a greater impact on their social, mental 
and pain functioning than patients with other chronic diseases 
(Osterhaus et al 1994). In addition, the results if this study 
found that different headache types had a signiﬁ  cant impact 
on the QoL, and that QoL varied according to headache 
disorders, with cluster headache having a larger impact on Neuropsychiatric Disease and Treatment 2008:4(3) 538
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social and pain function when compared to migraine, tension, 
or mixed headache disorders (Solomon et al 1993).
The assessment of headache-related QoL in children 
and adolescents is an emerging area of research. Despite the 
paucity of research on the impact of headache on perceived 
QoL, the available studies provide compelling evidence that 
demonstrate the negative impact of headaches on children’s 
QoL. Engstrom (1992) found that, in a sample of 20 head-
ache patients aged 9 to 18 years, children experienced 
more somatic complaints, lower general well-being, were 
less communicative, and experienced more physiologic 
anxiety than matched nonheadache controls. In another 
study of adolescents, participants with headaches reported 
worse psychological functioning, more physical symptoms, 
poorer functional status, and less satisfaction with life and 
heath than headache free controls (Langeveld et al 1996). 
Powers and colleagues (2003) found that in their study of 
572 pediatric patients between the ages of 5- and 18-years 
referred to a headache clinic, QoL was adversely affected in 
all areas of functioning when compared to healthy controls, 
and the impact on QoL was similar to that of children with 
juvenile rheumatoid arthritis and cancer. Finally, in a com-
munity sample of Swedish adolescents, Fichtel and Larsson 
(2002) found that adolescents with frequent headache had 
more functional disability when compared to those who had 
infrequent headache.
As a result of unpredictable and severe headaches, emo-
tional functioning may suffer as children experience repeated 
adjustment difﬁ  culties. Even in between headache attacks, 
the QoL of patients with recurrent headaches remains com-
promised. For example, children and adolescents may worry 
about whether a headache will start or worsen, fear that peers 
may not understand, worry about interference with social life 
and academic life, may experience a loss of control, and feel 
fed up, frustrated, angry, and worried (Cavallini et al 1995). 
The ability to perform everyday activities, such as going to 
school and participating in extracurricular activities, is impor-
tant for child and adolescent development, and limitations 
in these areas can have signiﬁ  cant negative psychological 
inﬂ  uences.
Therefore, incorporating reliable and valid pediatric-
speciﬁ  c measures of quality of life has important implications 
for treatment. The assessment of QoL in children is challeng-
ing, since measures must account for changes in cognitive 
and social development, and whether information is more 
accurate when obtained by child report versus parent report 
is debatable. The Pediatric Quality of Life Inventory, version 
4.0 (PedsQL 4.0) is a valid, developmentally appropriate 
measure designed to assess pediatric QoL in children between 
the ages of 2 and 18 years (Varni et al 2001). This brief 
23-item questionnaire is a general measure of QoL and has 
two forms, incorporating both parent and child responses. The 
PedsQL 4.0 has four age ranges: toddlers (2–4 years), young 
child (5–7 years), child (8–12 years), and adolescent (13–18 
years). The PedsQL asks respondents to indicate how much 
of a problem each item has been during the past month. The 
PedsQL 4.0 assesses QoL across four domains including: 
physical health, emotional, social, and school health. The 
questionnaire yields a total QoL score and two summary 
scores: Physical Health Summary Score and Psychosocial 
Health Summary Score.
When this instrument was compared across ages, it was 
found to be able to easily detect the impact of childhood 
headaches on the quality of life of children and adolescents 
(Powers et al 2004). In one study, a comparison of the QoL 
of children and adolescents with migraine with norms for 
healthy children and adolescents demonstrated impaired 
QoL in all areas of functioning (Powers et al 2003). Cross-
sectional comparisons within a migraine sample found 
differences in functional impairment across age groups, 
with adolescents (ages 13–18) reporting more impairment 
in School Functioning than children (ages 8–12) and young 
children (ages 5–7), and young children reporting more 
impairment in Social Functioning than children and adoles-
cents. When compared to other disease processes, including 
rheumatological diseases, oncological diseases, and cardiac 
diseases, although migraine did not separate out from these 
diseases, it was found to have a greater signiﬁ  cant impact 
on the quality of life, especially the emotional and school 
development (Powers et al 2003).
Measures of QoL, such as the PedsQL 4.0, can be effec-
tive tools in treatment planning and outcome measurement. 
In order for evaluation and management of headaches to be 
most successful, patient perspectives and goals should be 
accounted for. Thus, it is crucial to understand children’s 
and adolescents’ perceptions of the impact of headaches on 
their daily lives. Treatments that actively involve the patient’s 
perspective typically result in increases in the patient’s QoL, 
which are likely to bring about long term improvements in the 
overall QoL of the patient’s family as well. QoL instruments 
can be easily incorporated into clinical settings, as well as 
research protocols, to help inform practice and treatment.
Evaluation
One of the ﬁ  rst steps in the evaluation of a child with 
headache is to identify if it is attributed to a secondary cause. Neuropsychiatric Disease and Treatment 2008:4(3) 539
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This is done through a detailed headache history, including 
the length of time the child has had headaches, the severity 
of the headaches, the quality of the headache, location of the 
headache, as well as the impact on the child's quality of life 
and disability. The headache history also needs to include a 
detailed review of systems, past medical history, as well as a 
psychosocial and family history in order to identify warnings. 
Oftentimes, the parents and patients may have a preconceived 
determination as to the type of headache that the child has that 
is incorrect. A recent meta-analysis component of a practice 
parameter identiﬁ  ed that the most sensitive indicator of a 
need for further assessment is the neurological examination 
(Lewis et al 2002a). If abnormalities on the neurological 
examination cannot be explained by medical history, further 
investigation into the headache etiology is warranted and 
neuroimaging is most sensitive tool to detect a medically or 
surgically treatable cause.
Once the detailed history and neurological examination 
are performed, it is also useful to include a comprehensive 
headache exam (Linder 2005). This comprehensive headache 
exam can assist in identifying potential secondary causes, as 
well as being used to discuss with the family possible mis-
conceptions regarding the etiology of the headache.
Following the detailed history and medical examination, 
the primary caregiver should be able to determine whether the 
headaches are primary headaches or secondary headaches. 
If secondary headaches, it is essential to treat the secondary 
cause. If the headaches persist after resolution of the second-
ary cause, a reanalysis as to the etiology of the headaches 
must be considered.
Once secondary causes have been ruled out, the treatment 
of primary headaches can begin. In childhood, the most sig-
niﬁ  cant primary headache disorders brought to medical atten-
tion are migraine. This most commonly includes migraine 
without aura, probable migraine, migraine with aura, and 
chronic migraine.
Treatment
The treatment of primary headache disorders in children 
is threefold. The first component of treatment is acute 
therapy.
1.  Acute therapy is the treatment designed to abort the 
episodic headache. The goal of this treatment should be 
quick response, with return to normal activity and without 
relapse.
2.  The second component of treatment is preventative treat-
ment. When a child's headaches are frequent or there 
is signiﬁ  cant disability, preventative treatment must be 
considered with a goal of minimizing the impact of the 
headache while reducing the number. Although no deﬁ  ned 
frequency exists for preventative treatment, typically hav-
ing more than 2–3 headaches per month warrants treatment. 
This determination can be augmented by a disability instru-
ment such as PedMIDAS (Hershey et al 2001, 2004).
3.  The final component of treatment is biobehavioral 
therapy. This is a complex treatment that involves normal-
izing a child's lifestyle, as well as establishing long term 
healthy goals and promoting proper medication use.
Acute treatment
For the acute treatment of migraine, the National Headache 
Consortium Guideline recognized in adults that primary 
treatments can include nonspeciﬁ  c medications, as well as 
migraine-speciﬁ  c medications (Silberstein and Rosenberg 
2000). For children, the nonspeciﬁ  c medications are pri-
marily over-the-counter medications including nonsteroidal 
anti-inﬂ  ammatory drugs (NSAIDs; ibuprofen, naproxen 
sodium, and for older children aspirin), as well as general 
pain relievers (acetaminophen). Most prescriptive nonspe-
ciﬁ  c medications have either not been evaluated in children, 
or have not been proven statistically effective. Furthermore, 
many prescriptive medications contain sedatives or narcotics 
that may treat the pain, thus not allowing the child to return 
to normal functioning.
Hämäläinen and colleagues (1997) reported a compara-
tive, double-blinded, placebo-controlled, crossover study of 
placebo versus ibuprofen versus acetaminophen. Eighty-eight 
children with a clear diagnosis of migraine participated. 
These patients treated a migraine headache with either 
placebo, ibuprofen at a dose of 10 mg/kg, or acetaminophen 
at a dose of 15 mg/kg. Improvement in pain and pain free-
dom were assessed. The results of this study indicated that 
ibuprofen was superior to both placebo and acetaminophen 
at both the one and two-hour time point, while acetamino-
phen became superior to placebo at two hours. Lewis and 
colleagues (2002b) performed a similar study on a group 
of younger children using a dose of ibuprofen at 7.5 mg/kg 
versus placebo with a similar outcome, although there was 
a slight male-to-female difference.
Based on these studies, as well as the tolerability of ibu-
profen, it has become a mainstay for the acute treatment of 
childhood headache and migraines. Proper use of ibuprofen 
requires the child to learn to identify the onset of the headache 
in order to initiate rapid treatment, use the proper dose based 
on their weight and avoid overuse typically limiting it to no 
more than three times per week.Neuropsychiatric Disease and Treatment 2008:4(3) 540
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When NSAIDs are ineffective or not completely effective, 
migraine speciﬁ  c therapy is oftentimes required. Triptans are 
5HT-1B/D agonists, migraine-speciﬁ  c medications. There are 
currently seven triptans approved for use in the United States 
in adults, although none have been approved for the use of 
childhood migraine. This is largely due to study design and 
a large placebo effect seen in children, whereas the effect 
of the triptan was comparable to the adult studies. Several 
studies that were performed, however, did show their effec-
tiveness, including the use of sumatriptan both in tablet and 
nasal spray form (Linder and Dowson 2000), rizatriptan, and 
zolmitriptan, both in tablet and nasal spray form.
One of the initial studies in children was subcutaneous 
sumatriptan at a 0.06 mg/kg dose. The overall effectiveness was 
72% at 30 minutes, and 78% at two hours, with a low recurrence 
rate of 6% (Linder 1995). Injection of medication, however, is 
often rejected by children and this has limited its use.
Oral sumatriptan has been studied in a double-blinded, 
placebo control study with 25, 50 and 100 mg tablets 
(Winner et al 1996). The study’ s primary endpoint was at 
two hours. Headache response and statistical signiﬁ  cance 
was not reached due to a high placebo rate. Sumatriptan was, 
however, statistically signiﬁ  cant over the placebo at 25, 50 
and 100 mg at both the 180 and 240 minute mark, with 74% 
pain relief at the 4 hour mark. Headache recurrence rate 
remained lower in children than adults at an 18%–28% for 
sumatriptan, with no signiﬁ  cant adverse affects seen.
Sumatriptan nasal spray has been studied in randomized 
double-blinded placebo control trial in adolescents from 
12–17, for a single attack, using 5, 10 and 20 mg doses 
(Winner et al 2000). At 1 hour, 56% of patients using the 
10 or 20 mg dose reported significant headache relief, 
compared with 41% with placebo. If pain free response is 
examined, the 20 mg dose was statistically signiﬁ  cant with a 
46% response rate at 2 hours, compared to 25% for placebo. 
Associated symptoms were lower in the active medication 
group with photophobia signiﬁ  cantly lower with the 20 mg 
dose in 2 hours. A recent nasal sumatriptan study using 5 mg, 
20 mg and placebo dosing in a one-to-one ratio with 738 
adolescents did demonstrate that at 30 minutes a 20 mg dose 
had a greater headache relief (42% versus 43%, p = 0.046). At 
1 hour, this increased to 61% for active medicine versus 52% 
placebo (not signiﬁ  cant). By 2 hours response was increased 
to 68% for sumatriptan versus 58% for placebo (p = 0.025). 
There was also increased sustained release 1 through 24 hours 
and 2 through 24 hours (Winner et al 2000).
Rizatriptan 5 mg tablets have also been evaluated in the 
12–17 age group, with a double-blinded placebo controlled 
parallel group single attack study (Winner et al 2002). Of 
149 adolescents using rizatriptan, compared to 147 using 
placebo, the response rate at 2 hours for the rizatriptan 
group was 66%; whereas the placebo affect was 57%. 
The response of 66% in this study was comparable to the 
adult studies, although the placebo dose was much greater. 
Headache free rate at 2 hours was 32% for the rizatriptan 
group, compared to 28% in the placebo group with no seri-
ous adverse effects noted.
Zolmitriptan has also been studied in adolescents age 
12–17, using both the 2.5 mg and the 5 mg dose (Peroutka 
1997). The response rate was 88% and 70% respectively, 
with the treatment well tolerated. Nasal zolmitriptan was 
recently found to be effective, using a unique study design 
to minimize the placebo response rate. 248 adolescents were 
studied in a, randomized, double-blind, placebo-controlled, 2 
attack crossover trial with a single-blind placebo challenge. 
Seventy-seven patients responded to the placebo challenge 
and did not continue in the analysis. Of the remaining 171 
patients, zolmitriptan produced signiﬁ  cantly higher headache 
response rates than placebo at 1-hour post-dose (58.1% 
versus 43.3%; p  0.02), with an onset of action as early as 
15 minutes. Zolmitriptan also produced signiﬁ  cant pain-free 
response at 1 hour (27.7% vs. placebo 10.2%, p  0.001) 
and adolescents experienced a lower incidence of adverse 
events than usually seen in adults, with no serious adverse 
events or withdrawals (Peroutka 1997).
Two methods may be used for using triptans (Lipton 
et al 2000b). One is the rescue therapy or “stepwise 
treatment within an attack”, where the child starts with 
an NSAID at an appropriate dose at the onset of their 
headaches. If they recognize that this is not working, a 
triptan is used as rescue therapy. The alternative method 
is the “stratiﬁ  ed care model.” This requires the patient to 
determine the headache severity at the onset. For a mild 
or moderate headache, they take their NSAIDs, while for 
severe headaches, they take their triptans. In this way, 
the patient stratiﬁ  es their headaches and the subsequent 
treatment. This, however, has not been successful in 
children, as they oftentimes have difﬁ  culty recognizing 
the headache severity at its onset.
Recently, Burstein and Cutrer (2000). identiﬁ  ed cutane-
ous allodynia with central sensitization in adult migraine 
patients. In patients that do experience allodynia with cen-
tral sensitization, there is decreased response to medication 
once the allodynia has been established (Burstein et al 2000; 
Burstein and Jakubowski 2004). Allodynia can be thought 
of as extra peripheral sensation or heightening of activity in Neuropsychiatric Disease and Treatment 2008:4(3) 541
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sensation beyond the location of the headache or migraine. 
If a patient is identiﬁ  ed as having allodynia, it is important 
to stress the need for early treatment.
One precaution that must be taken with the use of 
acute medications is the avoidance of medication overuse. 
Medication overuse or analgesic rebound headaches are a 
frequent cause of transformed migraines or chronic daily 
headaches. It is characterized by inadequate treatment of 
headache with either a low-dose, or delayed treatment of 
the attack, resulting in an increasing use of the analgesic or 
medication over time with decreased effectiveness. When 
identiﬁ  ed, a recovery period free of analgesic use is required. 
It is imperative to notify the patients of the risk of analgesic 
overuse headache if any analgesic is used for more then 3 
headache per week.
A summary of treatment options can be found in Table 1.
Abortive therapy for migraine in children should focus 
on aborting an acute attack by controlling the aseptic 
inﬂ  ammation at the origin of the vasodilation and the pain. 
The ﬁ  rst line of treatment would be using an appropriate 
dose of anti-inﬂ  ammatory medications, such as ibuprofen 
(10 mg/kg), at onset of the headache in combination 
with rehydrating ﬂ  uids. The dose may be repeated once in 
3–4 hours for that headache.
Adequate response is deﬁ  ned headache freedom in 1–2 
hours, with patient back to baseline. If the headaches are still 
prolonged and not responding to anti-inﬂ  ammatory drugs, 
the use of triptans is warranted. Any triptan can be used as 
a rescue medication and repeated 2 hours later for the same 
headache. Triptans have some limitations for the number 
of headache per month (4–6 per month) they can be used for. 
They are not yet FDA-approved for use in children. 
Clinically, they are effective in children, and are frequently 
used for prolonged headaches.
When a headache does not respond to any of the above 
therapy, and lasts more than 72 hours, it will be deﬁ  ned as 
status migrainosus by the ICHD2 criteria and more aggres-
sive therapy is needed to prevent a transformation to chronic 
headache. The patient at that point should be referred to 
inpatient therapy starting in th emergency room.
Acute emergency department/inpatient 
treatment
Available speciﬁ  c treatments for migraine headache in an 
emergency room setting include the following: antidopaminer-
gic medication such as prochlorperazine and metochlopramide; 
NSAIDs such as ketorolac; dihydroergotamine (DHE); anti-
epileptic medications such as sodium valproate; and triptans. 
When this treatment does not work, a child may need to be 
admitted to the hospital for the treatment of status migrainous, 
an exacerbation of chronic severe headache or to check for an 
analgesic rebound headache. The goal of inpatient treatment 
is to control a headache that has been unresponsive to other 
abortive therapy and is disabling to the child.
Dopamine antagonists, including prochlorperazine and 
metoclopramide, were initially used for the nausea and 
vomiting effects of migraine headaches (Jones et al 1989). 
Subsequently, the dopaminergic model of migraine was 
developed, and these compounds have been re-analyzed for 
their usefulness in acute therapy (Peroutka 1997). Intrave-
nous (IV) formulation is superior to all of the formulations, 
with the oral route being ineffective, or showing only limited 
effectiveness.
Prochloroperazine has been shown to be very effective in 
aborting an attack in the emergency room when administered 
intravenously with a load of IV ﬂ  uids. Results show a 75% 
improvement with 50% headache freedom at one hour, and 
a 95% improvement with 60% headache freedom at 3 hours 
(Kabbouche et al 2001). When comparing prochlorperazine, 
metochlopramide and placebo in a randomized prospec-
tive double blinded placebo controlled study, the response 
to prochlorperazine was 82% improvement in headache 
severity, 42% with metoclopramide and 29% with placebo 
(Coppola et al 1995). The average dose of metoclopramide 
use is 0.13–0.15 mg/kg, with a maximum dose of 10 mg 
given intravenously over 15 minutes. These medications are 
usually well tolerated, but extrapyramidal reactions are more 
frequent in children compared to the older population, and an 
acute episode can easily be controlled in the emergency room 
Table 1 Different abortive treatment in children with migraine
Treatment of Migraine
Abortive








    5ht1b/1d/1f1a
 •   Ergotamine/
dihydroergotamine
    D 2, adrenergic, 5-HT1
♦ Ca-channel blockers
♦   Isometheptene compounds
(midrin, midrid)
♦   Dopamine antagonist 
(D2 receptor)
 • Metaclopramide
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with 25–50 mg of diphenhydramine given intravenously. 
These can often be used to break an acute episode of status 
migrainosus.
Ketorolac is often used in the emergency department as 
monotherapy for a migraine attack or in combination with other 
drugs. In monotherapy, the response to ketorolac is 55.2% 
improvement (Larkin 1999). When combined with prochlor-
perazine the response rate increases to 93% (Brousseau et al 
2004). Recurrence rate in 24 hours with ketorolac was 30%.
A possible explanation of this high rate of recurrence may 
be due to the use of ketorolac in patients with an analgesic 
rebound headache. These patients have been over-using 
their outpatient abortive treatment, including their NSAIDS. 
Ketorolac in these cases will only bring a temporary relief.
Ergot alkaloids have a long history of use in the humans, 
dating back over 400 years. They were ﬁ  rst recognized nearly 
100 years ago for their usefulness in migraines, with one of 
the most active forms being dihydroergotamine (DHE-45). 
Its effect is due to the 5HT1A-1B-1D-1F receptor agonist 
afﬁ  nity and central vasoconstriction. It has a greater alpha 
adrenergic antagonist activity than triptans, and is less 
vasoconstrictive peripherally. Although it was ﬁ  rst to be 
effective for migraine in 1945 (Horton et al 1945), it fell out 
of usefulness until Raskin (1986) reported its effectiveness. 
Subsequently, it has been synthesized and no longer has the 
complications from the puriﬁ  cation, and is used frequently in 
the inpatient, as well as emergency management of childhood 
headaches (Linder 1994). Limited reports have shown the 
usefulness of IV DHE in an inpatient setting to break status 
migrainosus or prolonged migraines in children, and may 
have further beneﬁ  t if premedicated with dopamine antago-
nists such as promethazine hydrochloride, or metoclopramide 
hydrochloride. More recently, nasal DHE has been used in 
adults. The extrapolation of the use in children, however, 
remains limited.
Single dose dihydroergotamine can be effective in the 
emergency room department. When compared to the valpro-
ate sodium, the response was similar for both at 1, 2, and 4 
hours, but DHE showed a better response at 24 hours, with 
90% headache free at 24 hours compared to 60% for the 
valproate (Edwards et al 2001). The effectiveness of these 
acute emergency department treatments in children and 
adolescents are limited but the reviews available show an 
acceptable outcome at 48–72 hours with a recurrence rate 
of 29%, which include the 6% who need a more prolonged 
inpatient treatment.
In-patient use of dihydroergotamine include two 
pediatric protocols that are recommended in children and 
adolescents. The ﬁ  rst one uses more frequent injections, 
but lower doses to prevent side effects, while the second 
protocol is more aggressive and uses higher doses for faster 
response. Before initiation of these protocols, girls who are 
of child bearing age should be evaluated for any concerns 
for pregnancy.
Low dose DHE (Larkin 1999)
DHE is administered with metoclopramide (0.2 mg/kg – 
maximum of 10 mg is given half an hour prior to the 
administration of the DHE) to prevent gastroenteral side 
effects. The dose of DHE varies with patient age.
DHE is repeated every 6 hours for a maximum of 
16 doses. When headache ceases, an extra dose of DHE is 
used to prevent recurrence. DHE dose may be increased by 
0.05 mg/dose until abdominal discomfort.
High dose DHE protocol (Kabbouche and Linder 2005)
Patients are premedicated with 0.13–0.15 mg/kg of prochlor-
perazine half an hour prior to the DHE dose. A dose of 0.5–1 
mg (depending on age and tolerability) is used every 8 hours 
until headache freedom. When headache ceases an extra dose 
is given. After 3 doses, the prochlorperazine is replaced by 
different antiemetic if signiﬁ  cant nausea persists to lessen the 
risk of extrapyramidal side effects. The response seen to this 
protocol is a 97% improvement and 77% headache freedom. 
Response starts being noticeable by dose #5 and can reach its 
maximum effects after dose 10. Side effects of DHE include 
nausea, vomiting, abdominal discomfort, ﬂ  ushed face, and 
increased blood pressure.
This therapy is continued every 8 hours till headache 
freedom, with a maximum of 20 doses.
There are no placebo controlled studies available, and the 
only review was a retrospective study reviewing reponse to 
treatment in children admitted to a pediatric neurology ﬂ  oor 
for the treatment of status migrainosus ().
Sodium valproate has been introduced in children recently 
as an abortive treatment for acute attacks, with promising 
responses. The mechanism in which sodium valproate acutely 
aborts migraine headaches is not well understood. Sodium 
valproate is given as a bolus of 15–20 mg per kg push (over 
5 minutes). This intravenous administration is to be followed 
by an oral dose (15–20 mg/day) within four hours after the 
injection (Mathew et al 2000; Tanen et al 2003). Studies 
examining the use of other anticonvulsant drugs have been 
inconclusive and will soon be repeated.
Recently, an inpatient use of sodium valproate has 
been suggested when DHE is contraindicated or has been Neuropsychiatric Disease and Treatment 2008:4(3) 543
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ineffective (Schwart et al 2002). A loading dose of 15 mg 
per kg is ﬁ  rst administered, and then followed with 5 mg/kg 
every 8 hours till headache freedom, or up to 10 doses, which-
ever comes ﬁ  rst. In adults with chronic daily headaches, this 
showed an 80% improvement.
The use of sodium valproate is deferred as the second line 
of treatment for status migrainosus due to the lack of stud-
ies reviewing beneﬁ  ts and responses, as well as guidelines 
and deﬁ  ned protocols. Multiple studies are available on the 
use of sodium valproate as a preventative medication, but 
not enough on acute therapy to get the medication to the 
forefront.
Prophylactic medication
The second component of effective headache treatment is 
preventative therapy or prophylactic medication. When a 
headache or migraine becomes highly frequent or disabling, 
preventative medications need to be considered. The goal of 
preventative treatment is a reduction of headache frequency 
and an improvement of headache disability. Prophylac-
tic medication can be largely grouped into antiepileptic 
medications, antidepressant medications, anti-serotonergic 
medications, and antihypertensive medications. As with 
the acute therapy, no prophylactic medication has been 
approved for the prevention of childhood migraine. Several 
studies have demonstrated the effectiveness of some of these 
medications.
In the antiepileptic medications, medications currently 
being used for the prevention of migraine include dival-
proate sodium, topiramate, gabapentin, levetiracetam, and 
zonisamide. For adult migraines, both divalproate sodium and 
topiramate have been approved for the prevention of adult 
migraines (Mathew et al 1995; Silberstein 1996).
For divalproate, a study of 31 children, aged 7–16, 
showed at a dose of 15–45 mg/kg a 76% responsiveness of 
a greater than 50% reduction in their headache frequency, 
while 18% had a greater than 75% reduction, and 6% were 
headache-free (Caruso et al 2000). A study using standard-
ized doses of either 500 or 1000 mg of divalproate in 9–17 
year-olds also reported a reduction in severity on the Visual 
Analog Scale from 6.8 to 0.7, with a decrease in headache 
frequency from 6 per month to 0.7 per month (Serdaroglu 
et al 2002).
In a large scale open label study, topiramate demonstrated 
its effectiveness over placebo (Bandell-Hoekstra et al 2000). 
In a study of 162 children from age 6–15, using a dose of 
2–3 mg/kg/day, with a maximum dose of 200 mg, topiramate 
resulted in a reduced mean monthly migraine rate over the 
entire double-blind phase of 2.6 days per month, compared 
to 2.0 days per month with placebo (Winner et al 2005). 
Although not statistically signiﬁ  cant, the trend was reﬂ  ective 
of this (p = 0.061). This was due to a large variation in the 
placebo-response group.
The effective dose for children for both of these medi-
cations is not known, but for divalproate sodium a dose of 
approximately 15–20 mg/kg/day and for topiramate, a dose of 
2–4 mg/kg/day appears to be effective. To achieve this dose, 
however, it must be tapered up slowly, typically increasing 
the dose in quarter steps over an 8–10 week period. In the 
case of topiramate, it is especially important to taper the 
dose slowly, as rapid titration may increase the side effects, 
especially the cognitive slowing.
Amitriptyline is the most widely used tricyclic antide-
pressant for headache prevention. Amitriptyline has been 
used for many decades for its antidepressive properties, and 
was ﬁ  rst recognized in the 1970s as an effective migraine 
therapy (Gomersall and Stuart 1973; Couch et al 1976; Couch 
and Hassesnein 1979). Most of the studies in children with 
amitriptyline have been open label studies, with no placebo-
controlled studies.
In a crossover study by Levinstein (1991) comparing 
amitriptyline with propranolol and cyproheptadine, amitrip-
tyline was found to be effective in 50%–60% of the children. 
In an open label study, amitriptyline resulted in a perceived 
improvement in over 80% of the children, with subsequent 
decrease in their frequency and impact of the child on head-
aches using a dose of 1 mg/kg/day (Hershey et al 2000). 
Due to its side effects, especially its somnolence, this must 
be slowly titrated to this dose, typically over an 8–10 week 
period, increasing it by 0.25 mg/kg/day every two weeks.
Cyproheptadine, an antihistamine with anti-serotonergic 
effects, has long been used for the prevention of childhood 
headaches (Bille et al 1977). In addition, it may also have 
some calcium channel-blocking properties (Peroutka and 
Allen 1984). Historic studies have shown the effectiveness 
in small groups of children with a dosage range of 0.2–0.4 
mg/kg/day. It tends to be well tolerated, with the most 
signiﬁ  cant side effect being increased weight gain. Due to 
the limitations in dosing and the signiﬁ  cance of the weight 
gain, it tends to be limited to the younger children, with less 
usefulness in teenagers.
Beta blockers have long been used for prevention of 
childhood headaches (Ludvigsson 1974; Ziegler and Hurwitz 
1993). Although one of the original studies did demonstrate 
effectiveness, follow-up studies have been more controver-
sial. In the recent practice parameter (Lewis et al 2004), Neuropsychiatric Disease and Treatment 2008:4(3) 544
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propranolol was found to have a mixed responsiveness when 
used for childhood headaches. Furthermore, the drop in blood 
pressure due to beta blockers, as well as exercise-induced 
asthma and depressive effects, oftentimes limits its usefulness 
in children. Given the above-mentioned alternatives, other 
choices may be more beneﬁ  cial for use in children, whereas 
the beta blockers may serve a more beneﬁ  cial use in adults, 
especially those with high blood pressure.
Calcium channel blockers have been extensively studied 
in adults for headache prevention. Flunarizine is a calcium 
channel blocker available in Europe, but not in the United 
States, and has been demonstrated to be an effective migraine 
preventive agent (Guidetti et al 1987; Sorge et al 1988). In 
children in a double-blinded placebo-controlled crossover 
study, the baseline headache frequency was reduced in the 
ﬂ  unarizine-treated compared to placebo. However, it is not 
currently available in the United States, and the use of other 
calcium channel blockers may not be as effective and cannot 
be extrapolated. One childhood study using nimodipine in a 
double-blinded placebo-controlled crossover study showed 
no signiﬁ  cant difference between the placebo and active drug 
group (Battistella et al 1990).
Additional prevention medications may include some 
nonpharmaceutical treatments, including both riboﬂ  avin 
(Schoenen et al 1998; Boehnke et al 2004) and coenzyme 
Q10 (Rozen et al 2002; Sandor et al 2005). Their effective-
ness and usefulness in children yet has to be determined.
One of the keys in the use of prophylactic medications is 
to slowly titrate the dose to an effective level. This requires 
an understanding by the parent and patient that it may take 
several weeks to months before an effective level is achieved, 
and therefore an effective response. Along with this comes 
the challenge of identifying a goal dose to achieve, based 
on the patient's size and weight. Oftentimes failure to respond 
to the preventative medication is due to inadequate treatment, 
either due to inadequate time of treatment or inadequate 
dosing. This can often be based on a patient’s and parents’ 
unrealistic expectation about the quickness with which they 
will respond to their treatment protocol. Educating the patient 
in the preventative therapy, as with their acute therapy, is 
essential to the patient's outcome.
It is necessary to emphasise to the patient the need of 
compliance with their prophylactic therapy. Any lack of 
compliance will not only increase the risk of side effects and 
decrease the chance of response, but also increase their risk 
in worsening their prognosis.
There are no risks of depency or tolerance when pre-
ventative medications are used. The main risk is resistance 
to one drug, and patients will then need to be switched to 
different therapy.
Rebound headache does not occur with preventative 
medication, by deﬁ  nition (ICHD2 criteria), rebound head-
ache is an analgesic overuse headache and occurs only 
when analgesics (acute medications) are used for more then 
3 headaches per week.
Biobehavioral treatment
Behavioral interventions provide a treatment option that can 
enhance, or if necessary, replace pharmacotherapy. The goals 
of behavioral treatments are to increase the patient’s control 
of their headaches, reduce related disability and affective 
distress, and limit reliance on poorly tolerated or unwanted 
medications.
Biobehavioral therapy for childhood headaches is not 
only essential for headache management, but also to maintain 
a lifetime response to the headache treatment. Biobehavioral 
therapy is generally divided into three components: treatment 
adherence, lifestyle management, and psychological inter-
vention including biofeedback assisted relaxation training.
Treatment adherence
Treatment adherence entails a clear understanding by the 
patient and parent about the importance of their treatment. 
Adherence is commonly deﬁ  ned as the “extent to which a 
patient's behavior coincides with medical or health advice” 
(Haynes 1979, pp.1–7). This deﬁ  nition delineates a range of 
patient behaviors (taking medications consistently, keeping 
clinic appointments, following special diets, making lifestyle 
changes) and suggests that patients' choice of behaviors may 
or may not align with medical recommendations. Identiﬁ  ed 
factors related to treatment nonadherence can be placed 
into one of three categories: (1) regimen characteristics 
(eg, changes in lifestyle, complexity), (2) disease charac-
teristics (eg, younger age of onset, symptom severity), and 
(3) patient/family variables (eg, premorbid/comorbid behav-
ioral and emotional problems, family dysfunction) (LaGreca 
and Schumann 1995).
Because the primary inﬂ  uences on adherence are likely 
to differ across individuals, psychological or biobehavioral 
interventions can help identify speciﬁ  c barriers to adherence 
to the medical plan for individual patients and assist with 
overcoming these barriers. Therefore, intervention strategies 
to increase treatment adherence are based on the needs of the 
patients and their families. Intervention strategies can have 
an educational focus, providing verbal and written instruc-
tion to patients and their parents about the management Neuropsychiatric Disease and Treatment 2008:4(3) 545
Migraine in adolescents
of headache symptoms. Educational strategies use factual 
information about the headaches and regimen requirements 
to explain the importance of treatment adherence. Interven-
tion strategies can also have a behavioral focus. Behavioral 
strategies target speciﬁ  c adherent behaviors to help patients 
incorporate lifestyle changes and medical regimens into their 
daily schedule. Visual reminders to cue behavior, such as 
charts for relaxation practice, self-monitoring, and rewards 
for treatment compliance are often used to help encourage 
adherent behaviors. Finally, in some cases, interventions 
may require clinical intervention strategies directed toward 
modifying behavioral and emotional difﬁ  culties displayed 
by patients and families. Intervention strategies may be used 
alone or in combination to help patients adhere to medical 
recommendations.
Lifestyle management
Biobehavioral therapy also involves adjustment of lifestyle 
habits. Many times, unhealthy lifestyle habits serve as a 
trigger for childhood headaches. For children, headache 
triggers often include inadequate nutrition, skipping meals, 
and altered sleep patterns. Intervention strategies assist 
patients and families with lifestyle changes by discussing the 
importance of maintaining healthy lifestyle habits. Speciﬁ  -
cally, interventions focus on the importance of adequate ﬂ  uid 
hydration with limited use of caffeine, place strong emphasis 
on regular exercise and adequate nutrition, including not skip-
ping meals and eating a balanced diet, and provide recom-
mendations for better sleep hygiene, such as consistent sleep 
and wake times and development of bedtime rituals.
Lifestyle interventions are focused on the acquisition and 
maintenance of healthy lifestyle habits. Behavioral therapy 
is frequently incorporated into treatment to identify and 
modify target behaviors. Behavioral intervention strategies 
emphasize maintenance of healthy behavior changes through 
self-regulatory behaviors, such as self-monitoring, and 
reinforcement-based procedures, such as contracting, contin-
gency management, and token systems. Emphasis is placed 
on the notion that these are lifetime goals that will control 
the impact of migraine and minimize the use of medication, 
which may result in an overall long term improvement in 
quality of life, as well as reversing any progressive nature 
of the disease.
Psychological intervention
A number of behavioral treatments have utility for migraine 
and tension-type headache. Self-regulation strategies, such 
as relaxation and biofeedback, as well as cognitive behavior 
therapies are reported as the most commonly used behavioral 
treatments for headache (Rains et al 2005). These treatments 
emphasize patient involvement and personal responsibility, 
facilitating the use of effective strategies for coping with 
pain and associated headache symptoms. Active involve-
ment of patients can lead to increased conﬁ  dence in abilities 
to prevent and manage headaches (Andrasik 2003), which 
in turn can lead to less headache-related disability (French 
et al 2000).
Relaxation skills are used to decrease headache by 
enabling patients to modify their own headache-related 
physiological responses and decrease sympathetic arousal 
(Rains et al 2005). Relaxation therapy teaches a variety of 
relaxation strategies for reducing tension and stress through-
out the body. Techniques commonly employed for headache 
treatment include: progressive muscle relaxation (PMR) to 
help children identify and discriminate between tense and 
relaxed muscle groups, autogenic training or cued relaxation, 
visualization and guided imagery, diaphragmatic breathing, 
and mini-relaxation, which focuses on a limited number of 
muscles in the head, neck, and shoulders. Children are taught 
techniques over several sessions, often 10 or more. Children 
are encouraged to practice these techniques daily and incor-
porate relaxation into daily life situations, particularly when 
headaches and feelings of stress tend to occur. Relaxation has 
resulted in generally positive effects with both migraine and 
tension-type headache (Andrasik and Shwartz 2006).
Biofeedback-assisted relaxation therapy may also be 
a useful addition to headache treatment (Daly et al 1983; 
Werder and Sargent 1984; Powers and Spirito 1998; 
Powers and Hershey 2002). Biofeedback refers to the use 
of electronic or electromechanical equipment to measure 
and then feed back information about physiologic functions. 
Biofeedback is also an ideal tool to assist pediatric patients 
in understanding and addressing the mind-body connection 
inherent in headache syndromes.
Biofeedback training involves teaching patients enhanced 
control over the physiological process. In headache treatment, 
thermal biofeedback has been used most often for migraine 
headache and electromyogram (EMG) biofeedback has been 
used for tension-type headache (Andrasik et al 2002).
Biofeedback may be coupled with relaxation therapy to 
teach children relaxation strategies for reducing tension and 
stress throughout the body, to teach controlled breathing 
techniques, such as diaphragmatic breathing, and to build 
conﬁ  dence in self-regulatory pain control. Although biofeed-
back training for headache may require several sessions, for 
children and adolescents, single-session biofeedback-assisted Neuropsychiatric Disease and Treatment 2008:4(3) 546
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relaxation therapy has been demonstrated to be learned 
quickly and efﬁ  ciently.
Beyond its value in providing information to patients 
about their bodies, biofeedback techniques can provide 
physiologic data that are helpful to the therapist to evalu-
ate progress or track behavioral responses to certain types 
of stimuli (eg, mental imagery). Throughout treatment, the 
therapist may wish to share this data with the patient to help 
reinforce progress, identify and understand behavioral pat-
terns, and facilitate the process of change.
Another common psychological intervention used in 
treatment of headaches is cognitive behavioral therapy. Cog-
nitive behavioral therapy is a treatment that targets behaviors, 
emotions, and cognitions that trigger or aggravate headaches 
(Rains et al 2005). The goal of cognitive behavior therapy is 
to help the patient modify overt behavior by altering thoughts, 
interpretations of events, assumptions, and typical behavior 
patterns of responding to stressors or events. Applied to 
headache, cognitive behavioral techniques alert patients to 
the role of thought processes in stress responses and the rela-
tionships between stress, coping, and headaches (Rains et al 
2005). Throughout treatment, patients are taught to develop 
more effective strategies for coping with headache related 
stress. Cognitive behavioral therapy can be administered in 
conjunction with relaxation or biofeedback training, during 
which patients are taught better awareness of their response 
patterns to a variety of interpersonal triggers.
Efﬁ  cacy of behavioral interventions
Over the past three decades, behavioral interventions have 
become standard components of the management of migraine 
headaches. Meta-analytic literature reviews of behavioral 
interventions have consistently identiﬁ  ed clinically signiﬁ  -
cant reductions in recurrent headache (Penzien et al 2002). 
Across studies, behavioral interventions have yielded 
approximately 35%–55% reduction in migraine headache 
activity from pre- to posttreatment (Penzien et al 2002)
Although researchers have only recently begun to com-
pare standard drug and nondrug treatments for migraine 
headache among pediatric populations, the available 
evidence suggests that the level of headache improvement 
with behavioral interventions may rival those obtained 
with widely used pharmacologic therapies. The two trials 
that have compared behavioral interventions and preventa-
tive drug therapies for pediatric migraine have each found 
behavior therapy, but not preventative drug therapy, effec-
tive in controlling migraines. One trial (Sartory et al 1998) 
compared two behavioral treatments (stress management 
plus relaxation or stress management plus biofeedback) 
and preventative medication (metropolol, 50 to 100 
mg/d). Relaxation lus stress management proved more 
effective than either biofeedback plus stress management 
or metropolol alone. An earlier trial (Olness et al 1987) 
used an incomplete triple crossover design in a placebo-
controlled comparison of the effectiveness of relaxation 
training with self-hypnosis and propranolol (3 mg/kg per 
day). The average number of migraines observed in the 3-
month propranolol and placebo periods did not differ, but 
signiﬁ  cantly fewer migraines were observed in the 3-month 
relaxation/self-hypnosis periods.
Various behavioral therapies for migraine headache have 
demonstrated effectiveness in both laboratory and clinical 
settings, and have become standard components of migraine 
headache treatment protocols in specialty headache centers 
and other similar settings. Although all treatments do not 
work the same for all patients, the integration of behav-
ioral therapies are important to consider in the selection of 
appropriate, effective treatments for adolescent migraine 
headache patients.
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